Cargando…

Total Hip Bone Mineral Density as an Indicator of Fracture Risk in Bisphosphonate‐Treated Patients in a Real‐World Setting

Bone mineral density (BMD) is an established measure used to diagnose patients with osteoporosis. In clinical trials, change in BMD has been shown to provide a reliable estimate of fracture risk reduction, and achieved BMD T‐score has been shown to reflect the near‐term risk of fracture. We aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Banefelt, Jonas, Timoshanko, Jen, Söreskog, Emma, Ortsäter, Gustaf, Moayyeri, Alireza, Åkesson, Kristina E., Spångéus, Anna, Libanati, Cesar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298264/ https://www.ncbi.nlm.nih.gov/pubmed/34585781 http://dx.doi.org/10.1002/jbmr.4448

Ejemplares similares

History of Previous Fracture and Imminent Fracture Risk in Swedish Women Aged 55 to 90 Years Presenting With a Fragility Fracture
por: Toth, Emese, et al.
Publicado: (2020)

Risk of imminent fracture following a previous fracture in a Swedish database study
por: Banefelt, J., et al.
Publicado: (2019)

Real-world effectiveness of osteoporosis treatment in the oldest old
por: Ström, O., et al.
Publicado: (2020)

Strontium ranelate effect on bone mineral density is modified by previous bisphosphonate treatment
por: Brun, Lucas R, et al.
Publicado: (2014)

Effects of Bisphosphonate Therapy on Bone Mineral Density in Boys with Duchenne Muscular Dystrophy
por: Ronsley, Rebecca, et al.
Publicado: (2020)

Estimating the Incidence and Key Risk Factors of Cardiovascular Disease in Patients at High Risk of Imminent Fracture Using Routinely Collected Real‐World Data From the UK
por: Pineda‐Moncusí, Marta, et al.
Publicado: (2022)

Additive effects of nutritional supplementation, together with bisphosphonates, on bone mineral density after hip fracture: a 12-month randomized controlled study
por: Flodin, Lena, et al.
Publicado: (2014)

Effect of vitamin D on bone mineral density of elderly patients with osteoporosis responding poorly to bisphosphonates
por: Heckman, George A, et al.
Publicado: (2002)

Comparison of the efficacy of three once-weekly bisphosphonates on bone mineral density gains in Korean women
por: Lee, Ji Hyun, et al.
Publicado: (2013)

Comparative effects of denosumab or bisphosphonate treatment on bone mineral density and calcium metabolism in postmenopausal women
por: Augoulea, A., et al.
Publicado: (2017)

Bone mineral density improves during 2 years of treatment with bisphosphonates in patients with ankylosing spondylitis
por: Arends, Suzanne, et al.
Publicado: (2020)

Effects of a 'Drug Holiday' on Bone Mineral Density and Bone Turnover Marker During Bisphosphonate Therapy
por: Kong, Sung Yeol, et al.
Publicado: (2013)

Efficacy and Safety of Bisphosphonates for Low Bone Mineral Density After Kidney Transplantation: A Meta-Analysis
por: Kan, Shun-Li, et al.
Publicado: (2016)

Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients
por: Kamimura, M., et al.
Publicado: (2016)

Difference in Bone Mineral Density Change at the Lateral Femoral Cortices according to Administration of Different Bisphosphonate Agents
por: Kim, Sungjun, et al.
Publicado: (2016)

Plain radiographic indices are reliable indicators for quantitative bone mineral density in male and female patients before total hip arthroplasty
por: Rohe, Sebastian, et al.
Publicado: (2023)

Skeletal responses to romosozumab after 12 months of denosumab
por: McClung, Michael R., et al.
Publicado: (2021)

Romosozumab efficacy and safety in European patients enrolled in the FRAME trial
por: Langdahl, Bente, et al.
Publicado: (2022)

Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals
por: Cosman, Felicia, et al.
Publicado: (2021)

Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data
por: Bell, Katy J L, et al.
Publicado: (2009)

Managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition
por: Van Poznak, Catherine
Publicado: (2010)

Comparison between teriparatide and bisphosphonates for improving bone mineral density in postmenopausal osteoporosis patients: A meta-analysis
por: Fan, Guiyong, et al.
Publicado: (2020)

Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial
por: van Hellemond, Irene E. G., et al.
Publicado: (2020)

Effects of denosumab on bone mineral density and bone turnover markers in rheumatoid arthritis patients switching from bisphosphonates
por: Kaneko, Tetsuya, et al.
Publicado: (2019)

Comparison of bone mineral density in forearm and hip regions and evaluation of area of these 2 sites
por: Rajaei, Alireza, et al.
Publicado: (2022)

Differences in hip bone mineral density may explain the hip fracture pattern in osteoarthritic hips
por: Wolf, Olof, et al.
Publicado: (2009)

Association between childhood anthropometric indicators and bone mineral density in adulthood
por: de Freitas, Mileny Caroline Menezes, et al.
Publicado: (2023)

Unexpected rapid increase in bone mineral density by bisphosphonate therapy after multiple spinal fractures: a case report
por: Koiwai, Hidefumi, et al.
Publicado: (2019)

Peri-acetabular bone mineral density in total hip replacement
por: Gauthier, L., et al.
Publicado: (2013)

Discordance in diagnosis of osteoporosis using spine and hip bone densitometry
por: Moayyeri, Alireza, et al.
Publicado: (2005)

Cadmium and lead in blood in relation to low bone mineral density and tubular proteinuria.
por: Alfvén, Tobias, et al.
Publicado: (2002)

Parathyroid Hormone versus Bisphosphonate Treatment on Bone Mineral Density in Osteoporosis Therapy: A Meta-Analysis of Randomized Controlled Trials
por: Shen, Longxiang, et al.
Publicado: (2011)

Trajectories of Bone Remodeling Markers and Bone Mineral Density during Treatment with Strontium Ranelate in Postmenopausal Women Previously Treated with Bisphosphonates
por: Lima, Helisane, et al.
Publicado: (2014)

Combination therapy of anabolic agents and bisphosphonates on bone mineral density in patients with osteoporosis: a meta-analysis of randomised controlled trials
por: Lou, Shenghan, et al.
Publicado: (2018)

Comparing the Efficacy and Safety of Denosumab with Bisphosphonates in Increasing Bone Mineral Density in Patients with Prostate Cancer and Breast Cancer on Antihormonal Treatment
por: Razaq, Abdul, et al.
Publicado: (2019)

Anxiety Levels Predict Bone Mineral Density in Postmenopausal Women Undergoing Oral Bisphosphonates: A Two-Year Follow-Up
por: Martino, Gabriella, et al.
Publicado: (2021)

A novel economic framework to assess the cost-effectiveness of bone-forming agents in the prevention of fractures in patients with osteoporosis
por: Söreskog, E., et al.
Publicado: (2021)

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years
por: Ferrari, S., et al.
Publicado: (2015)

Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension
por: Miyauchi, Akimitsu, et al.
Publicado: (2019)

A Budget Impact Model to Estimate the Environmental Impact of Adopting RESPIMAT(®) Re-usable in the Nordics and Benelux
por: Ortsäter, Gustaf, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dgi5v1fmdi2pcb51t1q0t5ci7l